Shots:

• Neurimmune to receive $30M up front & is eligible to receive an additional contingent milestone of ~$730M upon achievement of development, regulatory and commercial milestones along with royalties on net sales of any approved therapies that emerges from the collaboration
• Alexion gets an exclusive license globally to develop, manufacture and commercialize NI006 & will be responsible for trial costs while Neurimmune will be responsible for the completion of the P-Ib clinical trial
• NI006 is an investigational human mAb that specifically targets misfolded transthyretin and is designed to address the pathology of ATTR-CM by the removal of amyloid fibril deposits in the heart

Ref: Cision | Image: Business Standard